Circular Genomics said data presented at CTAD 2026 show a blood test built from 34 circular RNAs identified people nearing symptomatic Alzheimer’s disease more accurately than plasma pTau217, a finding that may improve timing for U.S. research trials.
The company presented a biotech showcase and five posters at the Clinical Trials on Alzheimer’s Disease meeting. Its CircPath platform covers circular RNA biomarker discovery and testing and is available for research use only.
The NIH-funded study published in Nature Medicine examined 1,221 participants in the Knight-Alzheimer Disease Research Center discovery cohort. Researchers also tested the model in a 551-person Knight-ADRC replication cohort and a 1,767-person A4 cohort.
For biomarker-confirmed Alzheimer’s disease, the 34-circRNA model produced an area under the curve of 0.945, compared with 0.877 for plasma pTau217. Using both markers together lifted the measure to 0.977. An area under the curve reflects how well a test distinguishes between people with and without the condition.
In the Knight-ADRC discovery cohort, the circRNA model’s hazard ratio for progression to symptomatic Alzheimer’s disease was 2.92, versus 1.81 for pTau217 alone. Participants who tested positive for both markers had a 4.83 hazard ratio compared with those negative for both; 84% of the dual-positive group progressed to Alzheimer’s disease, versus 15% of the dual-negative group.
For progression expected within five years, the circRNA model recorded an AUC of 0.870, compared with 0.676 for pTau217. The hazard ratio was 3.83 in the 551-person Knight-ADRC replication cohort and 13.95 when combined with pTau217. In the 1,767-person A4 cohort, the corresponding figures were 2.93 and 4.58.
A time-to-onset analysis found significant circRNA changes roughly two to four years before estimated symptom onset. Richard Hodes, director of the National Institute on Aging, said that identifying patients “on the verge of symptom onset would be invaluable” in a clinical setting.
The researchers reported low predictive power for Parkinson’s disease, dementia with Lewy bodies and frontotemporal dementia. They said larger prospective studies are needed and cautioned that the study did not establish whether the blood signals came directly from the brain.
Carlos Cruchaga, the study’s corresponding author, said patients receiving Aβ-removal therapies can become pTau-negative while still having Alzheimer’s disease. Nikolaos Mellios, Circular Genomics’ co-founder and chief scientific officer, said in a company statement carried by PR Newswire that the signature reflects synaptic, inflammatory and metabolic changes before symptoms appear.



